Singular Genomics Systems Stock Book Value Per Share
| OMIC Stock | USD 0.38 0.01 2.70% |
Singular Genomics Systems fundamentals help investors to digest information that contributes to Singular Genomics' financial success or failures. It also enables traders to predict the movement of Singular Stock. The fundamental analysis module provides a way to measure Singular Genomics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Singular Genomics stock.
| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 2.46 | 1.54 | |
| Tangible Book Value Per Share | 2.46 | 1.54 |
Singular | Book Value Per Share |
Singular Genomics Systems Company Book Value Per Share Analysis
Singular Genomics' Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.
More About Book Value Per Share | All Equity Analysis
Book Value per Share | = | Common EquityAverage Shares |
Current Singular Genomics Book Value Per Share | 2.42 X |
Most of Singular Genomics' fundamental indicators, such as Book Value Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Singular Genomics Systems is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Singular Book Value Per Share Driver Correlations
Understanding the fundamental principles of building solid financial models for Singular Genomics is extremely important. It helps to project a fair market value of Singular Stock properly, considering its historical fundamentals such as Book Value Per Share. Since Singular Genomics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Singular Genomics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Singular Genomics' interrelated accounts and indicators.
Click cells to compare fundamentals
The naive approach to look at Book Value per Share is to compare it to current stock price. If Book Value per Share is higher than the currently traded stock price, the company can be considered undervalued. However, investors must be aware that conventional calculation of Book Value does not include intangible assets such as goodwill, intellectual property, trademarks or brands and may not be an appropriate measure for many firms.
| Competition |
Singular Common Stock Shares Outstanding
Common Stock Shares Outstanding |
|
In accordance with the recently published financial statements, the book value per share of Singular Genomics Systems is about 2.425 times. This is 242.65% lower than that of the Health Care Equipment & Supplies sector and 80.81% lower than that of the Health Care industry. The book value per share for all United States stocks is 99.87% higher than that of the company.
Singular Book Value Per Share Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Singular Genomics' direct or indirect competition against its Book Value Per Share to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Singular Genomics could also be used in its relative valuation, which is a method of valuing Singular Genomics by comparing valuation metrics of similar companies.Singular Genomics is currently under evaluation in book value per share category among related companies.
Singular Fundamentals
| Return On Equity | -0.43 | ||||
| Return On Asset | -0.21 | ||||
| Operating Margin | (23.39) % | ||||
| Current Valuation | (68.35 M) | ||||
| Shares Outstanding | 74.07 M | ||||
| Shares Owned By Insiders | 14.01 % | ||||
| Shares Owned By Institutions | 47.17 % | ||||
| Number Of Shares Shorted | 667.17 K | ||||
| Price To Earning | 35.71 X | ||||
| Price To Book | 0.18 X | ||||
| Price To Sales | 10.86 X | ||||
| Revenue | 2.91 M | ||||
| Gross Profit | (24 K) | ||||
| EBITDA | (86.5 M) | ||||
| Net Income | (94.82 M) | ||||
| Cash And Equivalents | 287.98 M | ||||
| Cash Per Share | 4.05 X | ||||
| Total Debt | 75.29 M | ||||
| Debt To Equity | 0.20 % | ||||
| Current Ratio | 22.98 X | ||||
| Book Value Per Share | 2.42 X | ||||
| Cash Flow From Operations | (73.65 M) | ||||
| Short Ratio | 5.95 X | ||||
| Earnings Per Share | (1.30) X | ||||
| Price To Earnings To Growth | (0.15) X | ||||
| Target Price | 0.75 | ||||
| Number Of Employees | 255 | ||||
| Beta | 1.43 | ||||
| Market Capitalization | 28.23 M | ||||
| Total Asset | 265.47 M | ||||
| Retained Earnings | (337.6 M) | ||||
| Working Capital | 173.94 M | ||||
| Net Asset | 265.47 M |
About Singular Genomics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Singular Genomics Systems's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Singular Genomics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Singular Genomics Systems based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Singular Genomics Systems offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Singular Genomics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Singular Genomics Systems Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Singular Genomics Systems Stock:Check out Singular Genomics Piotroski F Score and Singular Genomics Altman Z Score analysis. You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Complementary Tools for Singular Stock analysis
When running Singular Genomics' price analysis, check to measure Singular Genomics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Singular Genomics is operating at the current time. Most of Singular Genomics' value examination focuses on studying past and present price action to predict the probability of Singular Genomics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Singular Genomics' price. Additionally, you may evaluate how the addition of Singular Genomics to your portfolios can decrease your overall portfolio volatility.
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories |
Is Singular Genomics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Singular Genomics. If investors know Singular will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Singular Genomics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.30) | Revenue Per Share 0.04 | Quarterly Revenue Growth 0.413 | Return On Assets (0.21) | Return On Equity (0.43) |
The market value of Singular Genomics Systems is measured differently than its book value, which is the value of Singular that is recorded on the company's balance sheet. Investors also form their own opinion of Singular Genomics' value that differs from its market value or its book value, called intrinsic value, which is Singular Genomics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Singular Genomics' market value can be influenced by many factors that don't directly affect Singular Genomics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Singular Genomics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Singular Genomics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Singular Genomics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.